This direct link between APTO253‐driven KLF4/MICA induction and enhanced NK cell‐mediated clearance reveals a novel therapeutic axis, offering a promising strategy to restore anti‐tumor immunity in AML [164]. The gene discussed is KLF4; the disease is acute myeloid leukemia.